Literature DB >> 9464821

Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.

J P Gaillard1, J Liautard, B Klein, J Brochier.   

Abstract

Interleukin-6 (IL-6) is a proinflammatory cytokine which possesses a central growth factor activity for certain tumor cells such as plasma cells in multiple myeloma (MM). Upon binding of IL-6, soluble IL-6 receptor (sIL-6R) has been shown to retain its affinity for IL-6 and to associate with the signal-transducing gp130 chain. Therefore, contrary to the majority of soluble cytokine receptors, it plays an agonist role in IL-6 signaling. In order to test its physiological importance as compared to that of its membrane counterpart, we studied cells from two myeloma cell lines which need exogenous IL-6 to proliferate and release sIL-6R into their culture supernatant. Using a new culture system where the supernatant recirculated permanently through an anti-IL-6R affinity column, all sIL-6R was removed from the culture medium throughout the culture period. Under these conditions IL-6-dependent cells were unable to grow in the presence of physiological concentrations of IL-6, showing the major role of the sIL-6R for sustaining the proliferation of these cell lines. Increasing IL-6 concentrations well over the physiological values allowed the cells to proliferate again. No effect was seen when sIL-6R was removed from the supernatant of an IL-6-independent myeloma cell line. These results show that the levels of circulating sIL-6R (and thus those of IL-6/sIL-6R complex) are worth looking at in pathologies involving IL-6 hyperactivity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9464821     DOI: 10.1002/eji.1830271232

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Protein kinase C delta and eta isoenzymes control the shedding of the interleukin 6 receptor alpha in myeloma cells.

Authors:  W Thabard; M Collette; R Bataille; M Amiot
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

2.  Susceptibility of human iris stromal cells to herpes simplex virus 1 entry.

Authors:  John Baldwin; Paul J Park; Brian Zanotti; Erika Maus; Michael V Volin; Deepak Shukla; Vaibhav Tiwari
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

3.  Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients.

Authors:  Jun Shoji; Atsuri Kawaguchi; Aki Gotoh; Noriko Inada; Mitsuru Sawa
Journal:  Jpn J Ophthalmol       Date:  2007-10-05       Impact factor: 2.447

4.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors:  Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2009-02-18       Impact factor: 22.113

5.  Hematologic neoplasias and acromegaly.

Authors:  Flavia Regina P Barbosa; Leonardo Vieira Neto; Giovanna Aparecida B Lima; Luiz Eduardo Wildemberg; Rodrigo Portugal; Monica R Gadelha
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

6.  Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.

Authors:  Michel Jourdan; Jérôme Moreaux; John De Vos; Dirk Hose; Karène Mahtouk; Matthieu Abouladze; Nicolas Robert; Marion Baudard; Thierry Rème; Angela Romanelli; Hartmut Goldschmidt; Jean-François Rossi; Michel Dreano; Bernard Klein
Journal:  Br J Haematol       Date:  2007-06-03       Impact factor: 6.998

Review 7.  The JAK-STAT pathway in hypertrophic stress signaling and genomic stress response.

Authors:  Michael A Wagner; M A Q Siddiqui
Journal:  JAKSTAT       Date:  2012-04-01

8.  A mathematical model for IL-6-mediated, stem cell driven tumor growth and targeted treatment.

Authors:  Fereshteh Nazari; Alexander T Pearson; Jacques Eduardo Nör; Trachette L Jackson
Journal:  PLoS Comput Biol       Date:  2018-01-19       Impact factor: 4.475

9.  BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

Authors:  Mohamed-Amine Hamouda; Arnaud Jacquel; Guillaume Robert; Alexandre Puissant; Valentine Richez; Romeo Cassel; Nina Fenouille; Sandrine Roulland; Jerome Gilleron; Emmanuel Griessinger; Alix Dubois; Beatrice Bailly-Maitre; Diogo Goncalves; Aude Mallavialle; Pascal Colosetti; Sandrine Marchetti; Martine Amiot; Patricia Gomez-Bougie; Nathalie Rochet; Marcel Deckert; Herve Avet-Loiseau; Paul Hofman; Jean-Michel Karsenti; Pierre-Yves Jeandel; Claudine Blin-Wakkach; Bertrand Nadel; Thomas Cluzeau; Kenneth C Anderson; Jean-Gabriel Fuzibet; Patrick Auberger; Frederic Luciano
Journal:  J Exp Med       Date:  2016-07-25       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.